Improve cognitive function in Parkinsons
- Trial ID
- NCT03836950
- Official Title
- rTMS as a Cognitive Rehabilitation Approach in Veterans With Parkinson's Disease
- Goal
- Improve cognitive function in Parkinsons
- Phase
- PHASE1, PHASE2
- Status
- RECRUITING
- Sponsor
- VA Office of Research and Development
- Study Type
- INTERVENTIONAL
- Enrollment
- 56 participants
- Conditions
- Parkinson's Disease, Mild Cognitive Impairment
- Interventions
- MagVenture MagProX100 stimulator (MagVenture, Falun, Denmark), MagVenture MagProX100 stimulator (MagVenture, Falun, Denmark)
Plain-Language Summary
The goal is to help veterans with Parkinson's who have mild cognitive impairment improve thinking and memory, especially attention and executive skills that affect daily life. The approach uses a MagVenture rTMS machine to deliver repeated magnetic pulses to targeted brain regions, boosting neuronal activity and strengthening networks involved in memory and attention; it is a non-drug, external therapy that does not directly change levodopa but requires participants to stay on stable Parkinson's medications. Eligible participants are veterans 50 or older seen at Hines or Jesse Brown VA with neurologist-confirmed Parkinson's or atypical parkinsonism and mild cognitive impairment, while people with dementia, prior deep brain stimulation, implanted pacemakers or metal in the head, a seizure history, severe tremor, or other conditions that raise seizure risk are excluded.
Locations
- Jesse Brown VA Medical Center, Chicago, IL, Chicago, Illinois, United States
- Edward Hines Jr. VA Hospital, Hines, IL, Hines, Illinois, United States
Frequently Asked Questions
- What is this trial testing?
- This trial is studying MagVenture MagProX100 stimulator (MagVenture, Falun, Denmark). The goal is to help veterans with Parkinson's who have mild cognitive impairment improve thinking and memory, especially attention and executive skills that affect daily life. The approach uses a MagVenture rTMS machine to deliver repeated magnetic pulses to targeted brain regions, boosting neuronal activity and strengthening networks involved in memory and attention; it is a non-drug, external therapy that does not directly change levodopa but requires participants to stay on stable Parkinson's medications. Eligible participants are veterans 50 or older seen at Hines or Jesse Brown VA with neurologist-confirmed Parkinson's or atypical parkinsonism and mild cognitive impairment, while people with dementia, prior deep brain stimulation, implanted pacemakers or metal in the head, a seizure history, severe tremor, or other conditions that raise seizure risk are excluded.
- Who can participate?
- Participants must be at least 50 Years.
- Where is this trial located?
- This trial is recruiting at 2 locations.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This Phase 1/Phase 2 trial is estimated to last approximately 7 years.